Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of V419/PR5I infant vaccination schedule
2010-021490-37Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2011
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of haemophilus influenzae type b vaccine and DTaP-IPV-Hep B-PRP-T vaccine in diphtheria, Tetanus, pertussis and 3 more (2 arms), sponsored by Sanofi. Primary endpoints: Vaccine-induced antibody response to PR5I and Immunogenicity of ProQuad when given concomitantly. Started Jan 2011; status: completed.
02
Drugs
haemophilus influenzae type b vaccineDTaP-IPV-Hep B-PRP-T vaccine
03
Conditions
diphtheriaTetanuspertussispoliomyelitisHaemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on 2010-021490-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021490-37.